Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 61Completed 38Unknown 33Not yet recruiting 27Active not recruiting 15Terminated 10Withdrawn 6Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Cisplatin 4130-nm albumin-bound paclitaxel 3camrelizumab 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Bevacizumab 2trilaciclib 1trastuzumab deruxtecan 1toripalimab 1selinexor 1sacituzumab govitecan 1ribociclib 1olaparib 1nimotuzumab 1lenvatinib 1fluorodopa F 18 1durvalumab 1decitabine and cedazuridine drug combination 1dalpiciclib 1cemiplimab 1carfilzomib 1apatinib 1anlotinib 1abemaciclib 1Valacyclovir 1Temozolomide 1Taxes 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enrolling by invitation × Injections × Clear all
NCT07121478 2025-10-01

Patients With High-grade Pancreatic Neuroendocrine Tumors

National Cancer Center, Korea

Phase 2 Enrolling by invitation
46 enrolled
EndocrineNET

Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡